Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00027443 · ClinicalTrials.gov registry record · NA
Study of Muromonab-CD3 and Cyclosporine in Patients With Giant Cell Myocarditis
A NA study, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 40
- Enrollment target
NCT00027443: Completed NA study, sponsored by Mayo Clinic.
NCT00027443 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00027443, a NA study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
Study Summary
This is a study to determine the efficacy of muromonab-CD3 and cyclosporine as treatment in patients with giant cell myocarditis (GCM). T lymphocytes appear to be involved in GCM. Muromonab-CD3 has been shown to reduce the number of lymphocytes and cyclosporine inhibits lymphocyte activation. This treatment may prolong patient survival until transplantation or ventricular assist device placement is possible.
Interventions
- DRUG Cyclosporine
- DRUG Muromonab-CD3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2001-08 |
| Est. Completion | 2007-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00027443
The ClinicalTrials.gov registry entry for NCT00027443 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cyclosporine is the first listed.
NCT00027443 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00027443 about?
NCT00027443 is a clinical study titled "Study of Muromonab-CD3 and Cyclosporine in Patients With Giant Cell Myocarditis". This is a study to determine the efficacy of muromonab-CD3 and cyclosporine as treatment in patients with giant cell myocarditis (GCM). T lymphocytes appear to be involved in GCM. Muromonab-CD3 has been shown to reduce the number of lymphocytes and cyclosporine inhibits lymphocyte activation. This t...
What is the current status of trial NCT00027443?
This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2001-08. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00027443?
The interventions under investigation include: Cyclosporine (DRUG), Muromonab-CD3 (DRUG).
Who is sponsoring clinical trial NCT00027443?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.